These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 2794068)

  • 1. Acute iron poisoning. Rescue with macromolecular chelators.
    Mahoney JR; Hallaway PE; Hedlund BE; Eaton JW
    J Clin Invest; 1989 Oct; 84(4):1362-6. PubMed ID: 2794068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
    Bergeron RJ; Wiegand J; Brittenham GM
    Blood; 2002 Apr; 99(8):3019-26. PubMed ID: 11929795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of oral deferiprone in acute iron poisoning.
    Berkovitch M; Livne A; Lushkov G; Segal M; Talmor C; Bentur Y; Klein J; Koren G
    Am J Emerg Med; 2000 Jan; 18(1):36-40. PubMed ID: 10674529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.
    Hallaway PE; Eaton JW; Panter SS; Hedlund BE
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10108-12. PubMed ID: 2481311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelation in acute iron poisoning and chronic hypersiderosis.
    Walsh JR; Gillick JB
    Clin Pediatr (Phila); 1965 Nov; 4(11):633-8. PubMed ID: 5844429
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute iron ingestion.
    Sipahi T; Karakurt C; Bakirtas A; Tavil B
    Indian J Pediatr; 2002 Nov; 69(11):947-9. PubMed ID: 12503657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
    Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
    Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute iron intoxication with deferoxamine: a report of six cases. Chelating agent proves effective in management of acute iron poisoning.
    Coli RD; Leone LA; Albala MM
    R I Med J; 1967 Aug; 50(8):549-53 passim. PubMed ID: 5235587
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First human studies with a high-molecular-weight iron chelator.
    Dragsten PR; Hallaway PE; Hanson GJ; Berger AE; Bernard B; Hedlund BE
    J Lab Clin Med; 2000 Jan; 135(1):57-65. PubMed ID: 10638695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dextran-coupled deferoxamine improves outcome in a murine model of head injury.
    Panter SS; Braughler JM; Hall ED
    J Neurotrauma; 1992; 9(1):47-53. PubMed ID: 1377753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative evaluation of two models of hemosiderosis for analysis of iron chelators].
    Minina LT; Prostakova TM; Meshchano AIu; Kol'tsova GN; Bovenko VN
    Biull Eksp Biol Med; 1996 Sep; 122(9):359-60. PubMed ID: 8974501
    [No Abstract]   [Full Text] [Related]  

  • 13. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron-chelating therapy.
    Hershko C; Weatherall DJ
    Crit Rev Clin Lab Sci; 1988; 26(4):303-45. PubMed ID: 3077034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current possibilities in the therapy of iron overload].
    Cermák J
    Vnitr Lek; 1994 Sep; 40(9):605-8. PubMed ID: 7975366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute liver failure due to iron overdose in an adult.
    Daram SR; Hayashi PH
    South Med J; 2005 Feb; 98(2):241-4. PubMed ID: 15759960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New advances in iron chelation therapy.
    Cohen AR
    Hematology Am Soc Hematol Educ Program; 2006; ():42-7. PubMed ID: 17124038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chelation of bismuth by combining desferrioxamine and deferiprone in rats.
    Tubafard S; Fatemi SJ
    Toxicol Ind Health; 2008 May; 24(4):235-40. PubMed ID: 19022876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-chelating therapy with the new oral agent ICL670 (Exjade).
    Cappellini MD
    Best Pract Res Clin Haematol; 2005 Jun; 18(2):289-98. PubMed ID: 15737891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of parenteral deferoxamine for acute iron poisoning.
    Tenenbein M
    J Toxicol Clin Toxicol; 1996; 34(5):485-9. PubMed ID: 8800185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.